ALFA Finder| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 25.3 | 26.1 | 30.6 |
| Other income | 1.5 | 0.2 | 0.4 |
| Total income | 26.8 | 26.3 | 31.0 |
| Profit before exceptional items & tax | 0.9 | 0.7 | 1.5 |
| Profit before tax | 0.9 | 0.7 | 1.5 |
| Net profit | 0.6 | 0.5 | 1.1 |
| Operating margin | 3.4% | 2.7% | 4.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -45.50% |
|---|---|
| Net profit, quarter on quarter | +20.00% |
| Revenue, year on year | -17.30% |
| Operating profit, year on year | -154.50% |
| Operating profit, quarter on quarter | -220.00% |
BSE results filing, NSE: TTFL. Figures extracted from the filing.
Trident Texofab Ltd: key numbers
- Share price
- ₹22.57
- Market cap
- ₹33.85 Cr
- Revenue (annual)
- ₹118.0 Cr
- Net profit (annual)
- ₹0.70 Cr
- P/E (TTM)
- -108.0×Sector 48.2×
- Promoter holding
- 32.88%+0.72% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Trident Texofab Ltd
All →Trident Texofab Other Announcement
Trident Texofab disclosed that its RTA, KFin Technologies, is shifting its corporate office to Kokapet, Hyderabad, effective 1 December 2026. The registered office stays unchanged and no financial impact is stated.
Trident Texofab Board Meeting Date
Trident Texofab schedules a board meeting on 5 November 2026 to consider unaudited quarterly results. No financial figures are disclosed yet.
Trident Texofab Annual General Meeting
Trident Texofab's EGM on 28 October 2026 sought approval for a statutory auditor to fill a casual vacancy. Only one ordinary resolution was tabled.
Trident Texofab Other Announcement
Trident Texofab Ltd has submitted its quarterly shareholding pattern filing for the period ending September 30, 2026, as per regulatory requirements.
Trident Texofab Management Change
Trident Texofab Limited has appointed M/s. A Bafna & Associates as the new Statutory Auditor for a term of 12 months.
Trident Texofab Board Meeting Outcome
Trident Texofab Ltd's board approved the appointment of a statutory auditor to fill a casual vacancy and convened an EGM for October 28, 2026.